UW-Madison researchers have discovered two peptides, HLTF;zf-C3HC4 and RO52;zf-C3HC4 (hereafter referred to as the HLTF peptide and the RO52 peptide) which, when tethered to a protein induce degradati...
Learn More

A UW-Madison researcher has engineered Lactobacillus reuteri (L. reuteri VPL1014) to express a recombinant gene from the chromosome or plasmid. The gene product can be rodent-, monkey-, or human-deriv...
Learn More

A UW-Madison researcher has engineered Lactobacillus reuteri (L. Reuteri VPL1014) to encode a native antirepressor protein whose expression is placed under the control of an inducible promoter along w...
Learn More

UW-Madison researchers have developed improved methods for optimizing the characteristics of salivary gland-derived mesenchymal stromal cells (MSCs) for therapeutic administration.The inventors have d...
Learn More

UW-Madison researchers and collaborators have developed a suite of four camelid antibodies that specifically bind to fentanyl and carfentanil, a major metabolite of fentanyl. One binds specifically to...
Learn More

UW-Madsion researchers have developed a method for reducing adiposity and promoting glucose homeostasis through consumption of tripropionin, a triglyceride containing three propionate fatty acids tail...
Learn More

UW-Madison researchers have developed a method for increasing butyrate production in the gut. The method includes delivering a microbial community that include certain bacteria, yeasts, and other micr...
Learn More

The development of small-molecule compounds that target the murine double minute 2 protein (MDM2) represents a significant advancement in cancer therapy. MDM2 is known to inhibit the tumor suppressor ...
Learn More

UW-Madison researchers have discovered methods for alleviating the adverse effects of SSRIs in pregnancy through the co-administration of the known drug ketanserin. Using several in vivo experimental ...
Learn More

UW Madison researchers have developed a virus-free, CRISPR-Cas mediated method of generating T cells that target senescent cells. These modified T cells could be used to treat Alzheimer’s Disease an...
Learn More

UW-Madison researchers have identified novel ACE2 mutants having enhanced activity and/or specificity in hydrolyzing angiotensin II. ACE2 (angiotensin converting enzyme 2) is a key metalloprotease of ...
Learn More

UW-Madison researchers have developed a novel fusion protein for inducing Breg cell formation and a method for transforming any human B cell into an IL10-competent, functional Breg cell ex vivo at sca...
Learn More

A composition for the treatment of bladder fibrosis in a patient in need that includes a miR-29 mimic is disclosed. The miR-29 mimic may include a working RNA strand with the nucleotide sequence UAGCA...
Learn More

Regulatory elements that drive Schwann cell-specific gene expression, nucleic acid vectors, virus particles, and therapeutic compositions incorporating these constructs; and methods of using these var...
Learn More

Friedreich’s Ataxia (FRDA) is a neurodegenerative disorder without treatments to halt or reverse disease progression, affecting roughly 9,000 Americans. FRDA is caused by triplet expansion in the fi...
Learn More

Pompe disease is a rare autosomal recessive genetic disease (mutations from both parent carriers have to be inherited by the offspring to see symptoms) that typically affects children during developme...
Learn More

Friedreich’s ataxia (also referred to as FA or FRDA) is a rare but fatal autosomal recessive neurodegenerative disease. With an estimated incidence of 1 in every 40,000 people, it causes progressive...
Learn More